Potential novel markers in IBD and CRC diagnostics. Are MMP-19 and RAGE promising candidates?
colorectal cancer
inflammatory bowel disease
matrix metalloproteinase
receptor of advanced glycation end-products
Journal
Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia
ISSN: 1804-7521
Titre abrégé: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
Pays: Czech Republic
ID NLM: 101140142
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
08
07
2021
accepted:
14
03
2022
pubmed:
31
3
2022
medline:
16
12
2022
entrez:
30
3
2022
Statut:
ppublish
Résumé
Inflammatory bowel diseases and colorectal cancer are serious intestinal disorders with continuously increasing incidence. Many aspects of etiopathogenesis still remain unclear. There is an urgent need to improve early diagnostics and markers indicating the progression of the disease. The aim of our study was to analyze the expression of matrix metalloproteinase-19 (MMP-19), and the receptor for advanced glycation end-products (RAGE) in different cell subpopulations in inflammatory bowel diseases (IBD) and colorectal cancer (CRC) compared to the tissue in the vicinity of pathological processes. Expression of both markers in epithelium, macrophages and vessels were evaluated in IBD and CRC groups. They were detected using immunohistochemistry in paraffin sections. There were significant differences between the expression of MMP-19 on macrophages and vessels among healthy and cancer tissues. In both, macrophages and vessels were significantly lower levels in cancer tissues. The expression of MMP-19 on vessels was also significantly different between peritumoral and cancer tissues (higher levels in peritumoral tissue). RAGE expression in macrophages was significantly different between healthy and cancer tissues and between peritumoral and cancer tissues. There was significantly lower expression in cancer tissues than in healthy and peritumoral tissues. Expression of RAGE in vessels was significantly different just in the comparison of healthy and peritumoral tissues (higher levels in healthy tissues). Both markers seem to be promising potential auxiliary markers in IBD and CRC diagnostics. They can also improve evaluation of disease progression.
Substances chimiques
matrix metalloproteinase 19
EC 3.4.24.-
Matrix Metalloproteinases, Secreted
EC 3.4.24.-
Receptor for Advanced Glycation End Products
0
Biomarkers
0
AGER protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
380-385Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Cervinková M, Horák P, Kanchev I, Matěj R, Fanta J, Sequens R, Kašpárek P, Sarnová L, Turečková J, Sedláček R. Differential expression and processing of matrix metalloproteinase 19 marks progression of gastrointestinal diseases. Folia Biol 2014;60(3):113-22.
Atkinson SJ, Ward RV, Reynolds JJ, Murphy G. Cell-mediated degradation of type IV collagen and gelatin films is dependent on the activation of matrix metalloproteinases. Biochem J 1992;288 (Pt 2):605-11.
pubmed: 1463464
doi: 10.1042/bj2880605
Murphy G, Knäuper V, Cowell S, Hembry R, Stanton H, Butler G, Freije J, Pendás AM, López-Otín C. Evaluation of some newer matrix metalloproteinases. Ann N Y Acad Sci 1999;878:25-39.
pubmed: 10415718
doi: 10.1111/j.1749-6632.1999.tb07672.x
Cui N, Hu M, Khalil RA. Biochemical and Biological Attributes of Matrix Metalloproteinases. Prog Mol Biol Transl Sci 2017;147:1-73.
pubmed: 28413025
doi: 10.1016/bs.pmbts.2017.02.005
Murphy G, Nagase H. Progress in matrix metalloproteinase research. Mol Aspects Med 2008;29(5):290-308.
pubmed: 18619669
doi: 10.1016/j.mam.2008.05.002
Zhao H, Yang Z, Wang X, Zhang X, Wang M, Wang Y, Mei Q, Wang Z. Triptolide inhibits ovarian cancer cell invasion by repression of matrix metalloproteinase 7 and 19 and upregulation of E-cadherin. Exp Mol Med 2012;44(11):633-41.
pubmed: 22902510
doi: 10.3858/emm.2012.44.11.072
Pendás AM, Folgueras AR, Llano E, Caterina J, Frerard F, Rodríguez F, Astudillo A, Noël A, Birkedal-Hansen H, López-Otín C. Diet-induced obesity and reduced skin cancer susceptibility in matrix metalloproteinase 19 deficient mice. Mol Cell Biol 2004;24(12):5304-13.
doi: 10.1128/MCB.24.12.5304-5313.2004
Jost M, Folgueras AR, Frérart F, Pendas AM, Blacher S, Houard X, Berndt S, Munaut C, Cataldo D, Alvarez J, Melen-Lamalle L, Foidart JM, López-Otín C, Noël A. Earlier onset of tumoral angiogenesis in matrix metalloproteinase-19-deficient mice. Cancer Res 2006;66(10):5234-41.
pubmed: 16707448
doi: 10.1158/0008-5472.CAN-05-4315
Brauer R, Beck IM, Roderfeld M, Roeb E, Sedlacek R. Matrix metalloproteinase-19 inhibits growth of endothelial cells by generating angiostatin-like fragments from plasminogen. BMC Biochem 2011;12:38.
pubmed: 21787393
doi: 10.1186/1471-2091-12-38
Chan KC, Ko JM, Lung HL, Sedlacek R, Zhang ZF, Luo DZ, Feng ZB, Chen S, Chen H, Chan KW, Tsao SW, Chua DT, Zabarovsky ER, Stanbridge EJ, Lung ML. Catalytic activity of Matrix metalloproteinase-19 is essential for tumor suppressor and anti-angiogenic activities in nasopharyngeal carcinoma. Int J Cancer 2011;129(8):1826-37.
pubmed: 21165953
doi: 10.1002/ijc.25855
Alkim C, Alkim H, Koksal AR, Boga S, Sen I. Angiogenesis in Inflammatory Bowel Disease. Int J Inflam 2015;2015:970890.
pubmed: 26839731
doi: 10.1155/2015/970890
Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, Pober JS, Wick TM, Konkle BA, Schwartz BS, Barnathan ES, McCrae KR, Hug BA, Schmidt AM, Stern DM. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998;91(10):3527-61.
Fonseca CG, Barbacena P, Franco CA. Endothelial cells on the move: dynamics in vascular morphogenesis and disease. Vasc Biol 2020;2(1):H29-H43.
doi: 10.1530/VB-20-0007
Hatoum OA, Heidemann J, Binion DG. The intestinal microvasculature as a therapeutic target in inflammatory bowel disease. Ann N Y Acad Sci 2006;1072:78-97.
doi: 10.1196/annals.1326.003
Azizian-Farsani F, Abedpoor N, Hasan Sheikhha M, Gure AO, Nasr-Esfahani MH, Ghaedi K. Receptor for Advanced Glycation End Products Acts as a Fuel to Colorectal Cancer Development. Front Oncol 2020;10:552283.
doi: 10.3389/fonc.2020.552283
Hegab Z, Gibbons S, Neyses L, Mamas MA. Role of advanced glycation end products in cardiovascular disease. World J Cardiol 2012;4(4):90-102.
doi: 10.4330/wjc.v4.i4.90
Ramasamy R, Yan SF, Schmidt AM. Advanced glycation endproducts: from precursors to RAGE: round and round we go. Amino Acids 2012;42(4):1151-61.
pubmed: 20957395
doi: 10.1007/s00726-010-0773-2
Akirav EM, Preston-Hurlburt P, Garyu J, Henegariu O, Clynes R, Schmidt AM, Herold KC. RAGE expression in human T cells: a link between environmental factors and adaptive immune responses. PLoS One 2012;7(4):e34698.
pubmed: 22509345
doi: 10.1371/journal.pone.0034698
Maillard-Lefebvre H, Boulanger E, Daroux M, Gaxatte C, Hudson BI, Lambert M. Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases. Rheumatology 2009;48(10):1190-6.
pubmed: 19589888
doi: 10.1093/rheumatology/kep199
Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe 1987;8(3):138-40.
pubmed: 3303008